E-mail: nrrfr99@gmail.com

Web: http://www.nrrfr.com/E/index.asp

Office Phone: 0086 10 58411195

Fax: 0086 10 58411195

Mob: 0086 18942662926

Post Code: 101601

Address: No. 27, Yingbin North Road, Yanjiao, Beijing East, China



Introduction of Neurorestoratology Center and Second Generation (2G) of Neurorestoration therapy (NT)



Neurorestoratology is a frontier discipline in 21st century. Neurorestoratology center at Jingdong Zhongmei Hospital headed by Professor Hong-yun HUANG is a research and treatment center of the global earliest translational clinical study of neurorestorative research with the most comprehensive clinical strategies and the best clinical outcome for the patients with various nervous disorders. It is leading this discipline development around the world.

Professor HUANG, as the founder of the International Association of Neurorestoratology (IANR), since 2001, his team first carried out the modern cell therapy in the spinal cord injury (SCI), motor neuron diseases (MNDs) or amyotrophic lateral sclerosis (ALS) and other intractable neurological diseases in the world. So far, over 1800 patients came from more than eighty countries, mainly Europe and North America.

Then this team established and is currently carrying out second generation of neurorestoration therapy (version 2.0 or 2G), a multi-cell, multi-route, multi-process and combination with multi-treatments. It can reach the largest and most effective neurological restoration by multi-route cell implantation and the optimizing cellular combination with the most appropriate nerve stimulation and drugs, and Active movement-Target enhancement - Neurorehabilitation therapy (AMTENT), according to the personal medical status of each patient. Treatment results by version 2.0 are better than by any single cell (including various stem cells) of first generation of neurorestoration therapy (version 1.0)

(1) Cells include olfactory ensheathing cells, neural stem / progenitor cells, Schwann cells, umbilical cord mesenchymal stem cells, autologous bone marrow mesenchymal stem cells, autologous nasal olfactory stem cells, etc.

(2) Routes include (a) brain and spinal cord injection (CT-guided or open surgery), (b) intrathecal implant by cervical puncture, thoracic puncture, lumbar puncture, cisterna magna puncture according to impairment site, and (c) intravascular.

(3) Combination multi-treatments include electrical nerve stimulation, acupuncture, AMTENT, medication and other treatment for neurorestoration.

Second generation of neurorestoration therapy (version 2.0 or 2G) has been able to: let the patient sit up from lying, stand up from sitting, and re-walk from standing; therefore it is no longer a dream for patients with complete chronic spinal cord injury to re-stand and re-walk. It has made the dream came true that MND or ALS and Alzheimer's disease (AD) could reverse or stabilize neurological deterioration, that patients with stroke sequelae have opportunity to improve the quality of life, and children with cerebral palsy (CP) have the capability of ameliorating intelligence and self-care ability.

Neurorestoratology center team dedicated themselves to promote rapid coordinated development between basic research and clinical application, with quick new translational creation of clinical treatment strategy from the preclinical research in order to benefit patients getting more from the advanced medical science and technology achievements.



Treated diseases

l Neurological damage ( spinal cord injury, brain trauma and peripheral nerve injury);

l Stroke;

l Cerebral palsy;

l Nerurological degeneration diseases;

l Sequle of encephalitis, meningitis and myelitis;

l Intractable pain;

l Neuropsychological diseases and others